title: Parenteral oestrogen: effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?
authors.affiliation: Department of Surgery and Cancer, Imperial College Faculty of Medicine , London , UK , and.
authors.forename: Syed I A
authors.initials: SI
authors.lastname: Shah
authors.forename: Paul D
authors.initials: PD
authors.lastname: Abel
authors.forename: Trinh
authors.initials: T
authors.lastname: Duong
authors.forename: Pat
authors.initials: P
authors.lastname: Price
authors.forename: Ruth
authors.initials: R
authors.lastname: Langley
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006177:Gynecomastia / Q000453:epidemiology; D006801:Humans; D007006:Hypogonadism / Q000453:epidemiology; D007273:Injections, Intramuscular; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D004967:Estrogens